UnknownNot Applicable

Outcomes Using MARS for Patients With ALF

United States30 participantsStarted 2021-04-23

Plain-language summary

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure • The patient underwent at least one round of dialysis using plasma exchange or MARSTM Exclusion Criteria: * Patient not meeting the inclusion criteria will be excluded. All patients who underwent MARS at MDMC will be included in the study population.

What they're measuring

Transplant free survival mortality

Timeframe: Rate at 30 days

Difference in Demographics

Timeframe: Rate at 30 days

Improvement in Transplant

Timeframe: Rate at 30 days

Trial details

NCT IDNCT05594953

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Crystee Cooper, DHEd

214-947-1280 clinicalresearch@mhd.com

View on ClinicalTrials.gov More Alcoholic Hepatitis trials